Literature DB >> 29053775

Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis.

Gourab Datta1, Alessandro Colasanti1,2, Eugenii A Rabiner3,4, Roger N Gunn1,3, Omar Malik1, Olga Ciccarelli5,6, Richard Nicholas1, Eline Van Vlierberghe7, Wim Van Hecke7, Graham Searle1,3, Andre Santos-Ribeiro1, Paul M Matthews1,8.   

Abstract

Brain magnetic resonance imaging is an important tool in the diagnosis and monitoring of multiple sclerosis patients. However, magnetic resonance imaging alone provides limited information for predicting an individual patient's disability progression. In part, this is because magnetic resonance imaging lacks sensitivity and specificity for detecting chronic diffuse and multi-focal inflammation mediated by activated microglia/macrophages. The aim of this study was to test for an association between 18 kDa translocator protein brain positron emission tomography signal, which arises largely from microglial activation, and measures of subsequent disease progression in multiple sclerosis patients. Twenty-one patients with multiple sclerosis (seven with secondary progressive disease and 14 with a relapsing remitting disease course) underwent T1- and T2-weighted and magnetization transfer magnetic resonance imaging at baseline and after 1 year. Positron emission tomography scanning with the translocator protein radioligand 11C-PBR28 was performed at baseline. Brain tissue and lesion volumes were segmented from the T1- and T2-weighted magnetic resonance imaging and relative 11C-PBR28 uptake in the normal-appearing white matter was estimated as a distribution volume ratio with respect to a caudate pseudo-reference region. Normal-appearing white matter distribution volume ratio at baseline was correlated with enlarging T2-hyperintense lesion volumes over the subsequent year (ρ = 0.59, P = 0.01). A post hoc analysis showed that this association reflected behaviour in the subgroup of relapsing remitting patients (ρ = 0.74, P = 0.008). By contrast, in the subgroup of secondary progressive patients, microglial activation at baseline was correlated with later progression of brain atrophy (ρ = 0.86, P = 0.04). A regression model including the baseline normal-appearing white matter distribution volume ratio, T2 lesion volume and normal-appearing white matter magnetization transfer ratio for all of the patients combined explained over 90% of the variance in enlarging lesion volume over the subsequent 1 year. Glial activation in white matter assessed by translocator protein PET significantly improves predictions of white matter lesion enlargement in relapsing remitting patients and is associated with greater brain atrophy in secondary progressive disease over a period of short term follow-up.
© The Author (2017). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  atrophy; microglia; multiple sclerosis; positron emission tomography; translocator protein

Mesh:

Substances:

Year:  2017        PMID: 29053775     DOI: 10.1093/brain/awx228

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  31 in total

Review 1.  Quantitative Rodent Brain Receptor Imaging.

Authors:  Kristina Herfert; Julia G Mannheim; Laura Kuebler; Sabina Marciano; Mario Amend; Christoph Parl; Hanna Napieczynska; Florian M Maier; Salvador Castaneda Vega; Bernd J Pichler
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

2.  Colocalization of neurons in optical coherence microscopy and Nissl-stained histology in Brodmann's area 32 and area 21.

Authors:  Caroline Magnain; Jean C Augustinack; Lee Tirrell; Morgan Fogarty; Matthew P Frosch; David Boas; Bruce Fischl; Kathleen S Rockland
Journal:  Brain Struct Funct       Date:  2018-10-17       Impact factor: 3.270

Review 3.  Positron emission tomography in multiple sclerosis - straight to the target.

Authors:  Benedetta Bodini; Matteo Tonietto; Laura Airas; Bruno Stankoff
Journal:  Nat Rev Neurol       Date:  2021-09-20       Impact factor: 42.937

4.  Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.

Authors:  Daniel S Reich; Douglas L Arnold; Patrick Vermersch; Amit Bar-Or; Robert J Fox; Andre Matta; Timothy Turner; Erik Wallström; Xinyan Zhang; Miroslav Mareš; Farit A Khabirov; Anthony Traboulsee
Journal:  Lancet Neurol       Date:  2021-09       Impact factor: 59.935

Review 5.  Neurobiology of migraine progression.

Authors:  Wanakorn Rattanawong; Alan Rapoport; Anan Srikiatkhachorn
Journal:  Neurobiol Pain       Date:  2022-06-09

Review 6.  Pharmacological considerations for treating neuroinflammation with curcumin in Alzheimer's disease.

Authors:  Xian Zhou; Madhuri Venigalla; Ritesh Raju; Gerald Münch
Journal:  J Neural Transm (Vienna)       Date:  2022-03-16       Impact factor: 3.850

7.  Atorvastatin ameliorates depressive behaviors and neuroinflammatory in streptozotocin-induced diabetic mice.

Authors:  Zhang Hai-Na; Yu Xu-Ben; Tang Cong-Rong; Cao Yan-Cheng; Yang Fan; Xu Lei-Mei; Sun Ruo-Lan; Wang Ye-Xuan; Liang Jing
Journal:  Psychopharmacology (Berl)       Date:  2019-11-30       Impact factor: 4.530

8.  Brain glial activation in fibromyalgia - A multi-site positron emission tomography investigation.

Authors:  Daniel S Albrecht; Anton Forsberg; Angelica Sandström; Courtney Bergan; Diana Kadetoff; Ekaterina Protsenko; Jon Lampa; Yvonne C Lee; Caroline Olgart Höglund; Ciprian Catana; Simon Cervenka; Oluwaseun Akeju; Mats Lekander; George Cohen; Christer Halldin; Norman Taylor; Minhae Kim; Jacob M Hooker; Robert R Edwards; Vitaly Napadow; Eva Kosek; Marco L Loggia
Journal:  Brain Behav Immun       Date:  2018-09-14       Impact factor: 7.217

Review 9.  PET imaging of neuroinflammation in neurological disorders.

Authors:  William C Kreisl; Min-Jeong Kim; Jennifer M Coughlin; Ioline D Henter; David R Owen; Robert B Innis
Journal:  Lancet Neurol       Date:  2020-11       Impact factor: 44.182

Review 10.  Traumatic Brain Injury and Risk of Neurodegenerative Disorder.

Authors:  Benjamin L Brett; Raquel C Gardner; Jonathan Godbout; Kristen Dams-O'Connor; C Dirk Keene
Journal:  Biol Psychiatry       Date:  2021-06-02       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.